{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:12:03Z","timestamp":1792066323953,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,25]],"date-time":"2016-07-25T00:00:00Z","timestamp":1469404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,7,25]],"date-time":"2016-07-25T00:00:00Z","timestamp":1469404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tumour hypoxia renders cancer cells resistant to cancer therapy, resulting in markedly worse clinical outcomes. To find clinical candidate compounds that reduce hypoxia in tumours, we conduct a high-throughput screen for oxygen consumption rate (OCR) reduction and identify a number of drugs with this property. For this study we focus on the anti-malarial, atovaquone. Atovaquone rapidly decreases the OCR by more than 80% in a wide range of cancer cell lines at pharmacological concentrations. In addition, atovaquone eradicates hypoxia in FaDu, HCT116 and H1299 spheroids. Similarly, it reduces hypoxia in FaDu and HCT116 xenografts in nude mice, and causes a significant tumour growth delay when combined with radiation. Atovaquone is a ubiquinone analogue, and decreases the OCR by inhibiting mitochondrial complex III. We are now undertaking clinical studies to assess whether atovaquone reduces tumour hypoxia in patients, thereby increasing the efficacy of radiotherapy.<\/jats:p>","DOI":"10.1038\/ncomms12308","type":"journal-article","created":{"date-parts":[[2016,7,25]],"date-time":"2016-07-25T05:33:08Z","timestamp":1469424788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":228,"title":["The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia"],"prefix":"10.1038","volume":"7","author":[{"given":"Thomas M.","family":"Ashton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Fokas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leoni A.","family":"Kunz-Schughart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Folkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6128-7998","authenticated-orcid":false,"given":"Selvakumar","family":"Anbalagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Huether","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Pirovano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca M.","family":"Buffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester M.","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stratford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth J.","family":"Muschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff S.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Gillies","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,25]]},"reference":[{"key":"BFncomms12308_CR1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/j.semnuclmed.2014.11.002","volume":"45","author":"N Dhani","year":"2015","unstructured":"Dhani, N., Fyles, A., Hedley, D. & Milosevic, M. The clinical significance of hypoxia in human cancers. Semin. Nucl. Med. 45, 110\u2013121 (2015).","journal-title":"Semin. Nucl. Med."},{"key":"BFncomms12308_CR2","first-page":"3289","volume":"51","author":"P Okunieff","year":"1991","unstructured":"Okunieff, P. et al. Angiogenesis determines blood flow, metabolism, growth rate, and ATPase kinetics of tumors growing in an irradiated bed: 31P and 2H nuclear magnetic resonance studies. Cancer Res. 51, 3289\u20133295 (1991).","journal-title":"Cancer Res."},{"key":"BFncomms12308_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","volume":"11","author":"WR Wilson","year":"2011","unstructured":"Wilson, W. R. & Hay, M. P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11, 393\u2013410 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"BFncomms12308_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.radonc.2011.03.004","volume":"100","author":"J Overgaard","year":"2011","unstructured":"Overgaard, J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis. Radiother. Oncol. 100, 22\u201332 (2011).","journal-title":"Radiother. Oncol."},{"key":"BFncomms12308_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1158\/0008-5472.CAN-11-2263","volume":"72","author":"E Fokas","year":"2012","unstructured":"Fokas, E. et al. Dual inhibition of the PI3K\/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res. 72, 239\u2013248 (2012).","journal-title":"Cancer Res."},{"key":"BFncomms12308_CR6","doi-asserted-by":"publisher","first-page":"20131124","DOI":"10.1098\/rsif.2013.1124","volume":"11","author":"DR Grimes","year":"2014","unstructured":"Grimes, D. R., Kelly, C., Bloch, K. & Partridge, M. A method for estimating the oxygen consumption rate in multicellular tumour spheroids. J. R. Soc. Interface 11, 20131124 (2014).","journal-title":"J. R. Soc. Interface"},{"key":"BFncomms12308_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.radonc.2014.02.007","volume":"111","author":"CJ Kelly","year":"2014","unstructured":"Kelly, C. J. et al. Regulation of O consumption by the PI3K and mTOR pathways contributes to tumor hypoxia. Radiother. Oncol. 111, 72\u201380 (2014).","journal-title":"Radiother. Oncol."},{"key":"BFncomms12308_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3109\/02841869509093981","volume":"34","author":"TW Secomb","year":"1995","unstructured":"Secomb, T. W., Hsu, R., Ong, E. T., Gross, J. F. & Dewhirst, M. W. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol. (Madr). 34, 313\u2013316 (1995).","journal-title":"Acta Oncol. (Madr)."},{"key":"BFncomms12308_CR9","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/cam4.112","volume":"2","author":"P Ellinghaus","year":"2013","unstructured":"Ellinghaus, P. et al. BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I. Cancer Med. 2, 611\u2013624 (2013).","journal-title":"Cancer Med."},{"key":"BFncomms12308_CR10","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1073\/pnas.0706585104","volume":"105","author":"X Lin","year":"2008","unstructured":"Lin, X. et al. A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation. Proc. Natl Acad. Sci. USA 105, 174\u2013179 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms12308_CR11","doi-asserted-by":"publisher","first-page":"e02242","DOI":"10.7554\/eLife.02242","volume":"3","author":"WW Wheaton","year":"2014","unstructured":"Wheaton, W. W. et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife 3, e02242 (2014).","journal-title":"eLife"},{"key":"BFncomms12308_CR12","doi-asserted-by":"publisher","first-page":"6741","DOI":"10.1158\/1078-0432.CCR-13-1787","volume":"19","author":"VE Zannella","year":"2013","unstructured":"Zannella, V. E. et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin. Cancer Res. 19, 6741\u20136750 (2013).","journal-title":"Clin. Cancer Res."},{"key":"BFncomms12308_CR13","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/S0021-9258(17)30124-2","volume":"254","author":"LJ Reitzer","year":"1979","unstructured":"Reitzer, L. J., Wice, B. M. & Kennell, D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J. Biol. Chem. 254, 2669\u20132676 (1979).","journal-title":"J. Biol. Chem."},{"key":"BFncomms12308_CR14","doi-asserted-by":"publisher","first-page":"17910","DOI":"10.1073\/pnas.0909353106","volume":"106","author":"K Lee","year":"2009","unstructured":"Lee, K. et al. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc. Natl Acad. Sci. USA 106, 17910\u201317915 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms12308_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1128\/CMR.8.3.427","volume":"8","author":"M Khaw","year":"1995","unstructured":"Khaw, M. & Panosian, C. B. Human antiprotozoal therapy: past, present, and future. Clin. Microbiol. Rev. 8, 427\u2013439 (1995).","journal-title":"Clin. Microbiol. Rev."},{"key":"BFncomms12308_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.canlet.2011.12.034","volume":"319","author":"Y Harada","year":"2012","unstructured":"Harada, Y., Ishii, I., Hatake, K. & Kasahara, T. Pyrvinium pamoate inhibits proliferation of myeloma\/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3. Cancer Lett. 319, 83\u201388 (2012).","journal-title":"Cancer Lett."},{"key":"BFncomms12308_CR17","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.1158\/1078-0432.CCR-04-2546","volume":"11","author":"GJ Veal","year":"2005","unstructured":"Veal, G. J. et al. Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. Clin. Cancer Res. 11, 5893\u20135899 (2005).","journal-title":"Clin. Cancer Res."},{"key":"BFncomms12308_CR18","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/jac\/dks504","volume":"68","author":"GL Nixon","year":"2013","unstructured":"Nixon, G. L. et al. Antimalarial pharmacology and therapeutics of atovaquone. J. Antimicrob. Chemother. 68, 977\u2013985 (2013).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFncomms12308_CR19","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1038\/ncomms5029","volume":"5","author":"D Birth","year":"2014","unstructured":"Birth, D., Kao, W. C. & Hunte, C. Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action. Nat. Commun. 5, 4029 (2014).","journal-title":"Nat. Commun."},{"key":"BFncomms12308_CR20","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1124\/mol.108.045120","volume":"73","author":"GA Biagini","year":"2008","unstructured":"Biagini, G. A. et al. Acridinediones: selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex. Mol. Pharmacol. 73, 1347\u20131355 (2008).","journal-title":"Mol. Pharmacol."},{"key":"BFncomms12308_CR21","doi-asserted-by":"publisher","first-page":"177ra137","DOI":"10.1126\/scitranslmed.3005029","volume":"5","author":"A Nilsen","year":"2013","unstructured":"Nilsen, A. et al. Quinolone-3-diarylethers: a new class of antimalarial drug. Sci. Transl. Med. 5, 177ra137 (2013).","journal-title":"Sci. Transl. Med."},{"key":"BFncomms12308_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0009-2797(99)00144-1","volume":"124","author":"W Knecht","year":"2000","unstructured":"Knecht, W., Henseling, J. & Loffler, M. Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem. Biol. Interact. 124, 61\u201376 (2000).","journal-title":"Chem. Biol. Interact."},{"key":"BFncomms12308_CR23","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1593\/neo.10168","volume":"12","author":"N Hail Jr","year":"2010","unstructured":"Hail, N. Jr, Chen, P. & Bushman, L. R. Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention. Neoplasia 12, 464\u2013475 (2010).","journal-title":"Neoplasia"},{"key":"BFncomms12308_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/A:1006859115450","volume":"174","author":"M Loffler","year":"1997","unstructured":"Loffler, M., Jockel, J., Schuster, G. & Becker, C. Dihydroorotat-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides. Mol. Cell. Biochem. 174, 125\u2013129 (1997).","journal-title":"Mol. Cell. Biochem."},{"key":"BFncomms12308_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0006-291X(68)90266-0","volume":"33","author":"HL Elford","year":"1968","unstructured":"Elford, H. L. Effect of hydroxyurea on ribonucleotide reductase. Biochem. Biophys. Res. Commun. 33, 129\u2013135 (1968).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFncomms12308_CR26","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1016\/S0021-9258(18)69710-8","volume":"234","author":"CA Pasternak","year":"1959","unstructured":"Pasternak, C. A. & Handschumacher, R. E. The biochemical activity of 6-azauridine: interference with pyrimidine metabolism in transplantable mouse tumors. J. Biol. Chem. 234, 2992\u20132997 (1959).","journal-title":"J. Biol. Chem."},{"key":"BFncomms12308_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0167-8140(97)00220-X","volume":"46","author":"J Overgaard","year":"1998","unstructured":"Overgaard, J. et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother. Oncol. 46, 135\u2013146 (1998).","journal-title":"Radiother. Oncol."},{"key":"BFncomms12308_CR28","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(03)14361-9","volume":"362","author":"J Overgaard","year":"2003","unstructured":"Overgaard, J. et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362, 933\u2013940 (2003).","journal-title":"Lancet"},{"key":"BFncomms12308_CR29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1269\/jrr.46.453","volume":"46","author":"C Sugie","year":"2005","unstructured":"Sugie, C. et al. Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo. J. Radiat. Res. 46, 453\u2013459 (2005).","journal-title":"J. Radiat. Res."},{"key":"BFncomms12308_CR30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.clon.2014.11.024","volume":"27","author":"MA Hassan Metwally","year":"2015","unstructured":"Hassan Metwally, M. A., Jansen, J. A. & Overgaard, J. Study of the population pharmacokinetic characteristics of nimorazole in head and neck cancer patients treated in the DAHANCA-5 trial. Clin. Oncol. (R. Coll. Radiol). 27, 168\u2013175 (2015).","journal-title":"Clin. Oncol. (R. Coll. Radiol)."},{"key":"BFncomms12308_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/bjc.1983.153","volume":"48","author":"J Overgaard","year":"1983","unstructured":"Overgaard, J., Overgaard, M. & Timothy, A. R. Studies of the pharmacokinetic properties of nimorazole. Br. J. Cancer 48, 27\u201334 (1983).","journal-title":"Br. J. Cancer"},{"key":"BFncomms12308_CR32","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1128\/AAC.40.3.556","volume":"40","author":"R Dixon","year":"1996","unstructured":"Dixon, R., Pozniak, A. L., Watt, H. M., Rolan, P. & Posner, J. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. Antimicrob. Agents Chemother. 40, 556\u2013560 (1996).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFncomms12308_CR33","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1592\/phco.19.13.1050.31598","volume":"19","author":"J Falloon","year":"1999","unstructured":"Falloon, J. et al. Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. Pharmacotherapy 19, 1050\u20131056 (1999).","journal-title":"Pharmacotherapy"},{"key":"BFncomms12308_CR34","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1128\/AAC.41.6.1319","volume":"41","author":"PE Rolan","year":"1997","unstructured":"Rolan, P. E., Mercer, A. J., Tate, E., Benjamin, I. & Posner, J. Disposition of atovaquone in humans. Antimicrob. Agents Chemother. 41, 1319\u20131321 (1997).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFncomms12308_CR35","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S0891-5849(00)00239-2","volume":"28","author":"C Beuneu","year":"2000","unstructured":"Beuneu, C. et al. Indirect inhibition of mitochondrial dihydroorotate dehydrogenase activity by nitric oxide. Free Radic. Biol. Med. 28, 1206\u20131213 (2000).","journal-title":"Free Radic. Biol. Med."},{"key":"BFncomms12308_CR36","doi-asserted-by":"publisher","first-page":"12828","DOI":"10.1073\/pnas.0910885107","volume":"107","author":"AA Khutornenko","year":"2010","unstructured":"Khutornenko, A. A. et al. Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway. Proc. Natl Acad. Sci. USA 107, 12828\u201312833 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms12308_CR37","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.cmet.2016.03.010","volume":"23","author":"NS Chandel","year":"2016","unstructured":"Chandel, N. S. et al. Are metformin doses used in murine cancer models clinically relevant? Cell Metab. 23, 569\u2013570 (2016).","journal-title":"Cell Metab."},{"key":"BFncomms12308_CR38","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.cmet.2016.03.006","volume":"23","author":"RJ Dowling","year":"2016","unstructured":"Dowling, R. J. et al. Metformin pharmacokinetics in mouse tumors: implications for human therapy. Cell Metab. 23, 567\u2013568 (2016).","journal-title":"Cell Metab."},{"key":"BFncomms12308_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","volume":"50","author":"GG Graham","year":"2011","unstructured":"Graham, G. G. et al. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 50, 81\u201398 (2011).","journal-title":"Clin. Pharmacokinet."},{"key":"BFncomms12308_CR40","first-page":"5522","volume":"56","author":"H Kimura","year":"1996","unstructured":"Kimura, H. et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res. 56, 5522\u20135528 (1996).","journal-title":"Cancer Res."},{"key":"BFncomms12308_CR41","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.semradonc.2013.05.006","volume":"23","author":"M Koritzinsky","year":"2013","unstructured":"Koritzinsky, M. & Wouters, B. G. The roles of reactive oxygen species and autophagy in mediating the tolerance of tumor cells to cycling hypoxia. Semin. Radiat. Oncol. 23, 252\u2013261 (2013).","journal-title":"Semin. Radiat. Oncol."},{"key":"BFncomms12308_CR42","doi-asserted-by":"publisher","first-page":"6801","DOI":"10.1007\/s13277-014-1928-7","volume":"35","author":"ZF Miao","year":"2014","unstructured":"Miao, Z. F. et al. Influence of different hypoxia models on metastatic potential of SGC-7901 gastric cancer cells. Tumour Biol. 35, 6801\u20136808 (2014).","journal-title":"Tumour Biol."},{"key":"BFncomms12308_CR43","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.3892\/or.2013.2401","volume":"29","author":"M Okajima","year":"2013","unstructured":"Okajima, M. et al. Anoxia\/reoxygenation induces epithelial-mesenchymal transition in human colon cancer cell lines. Oncol. Rep. 29, 2311\u20132317 (2013).","journal-title":"Oncol. Rep."},{"key":"BFncomms12308_CR44","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nprot.2014.018","volume":"9","author":"JK Salabei","year":"2014","unstructured":"Salabei, J. K., Gibb, A. A. & Hill, B. G. Comprehensive measurement of respiratory activity in permeabilized cells using extracellular flux analysis. Nat. Protoc. 9, 421\u2013438 (2014).","journal-title":"Nat. Protoc."},{"key":"BFncomms12308_CR45","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/bmc.1423","volume":"24","author":"S Gurule","year":"2010","unstructured":"Gurule, S., Goswami, D., Khuroo, A. H. & Monif, T. LC-APCI mass spectrometric method development and validation for the determination of atovaquone in human plasma. Biomed. Chromatogr. 24, 497\u2013505 (2010).","journal-title":"Biomed. Chromatogr."},{"key":"BFncomms12308_CR46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jpba.2007.10.007","volume":"46","author":"V Porta","year":"2008","unstructured":"Porta, V. et al. HPLC-UV determination of metformin in human plasma for application in pharmacokinetics and bioequivalence studies. J. Pharm. Biomed. Anal. 46, 143\u2013147 (2008).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"BFncomms12308_CR47","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ab.2009.07.026","volume":"394","author":"S Chaiyarit","year":"2009","unstructured":"Chaiyarit, S. & Thongboonkerd, V. Comparative analyses of cell disruption methods for mitochondrial isolation in high-throughput proteomics study. Anal. Biochem. 394, 249\u2013258 (2009).","journal-title":"Anal. Biochem."},{"key":"BFncomms12308_CR48","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1101\/gad.1970810","volume":"24","author":"J Moss","year":"2010","unstructured":"Moss, J. et al. Break-induced ATR and Ddb1-Cul4(Cdt)(2) ubiquitin ligase-dependent nucleotide synthesis promotes homologous recombination repair in fission yeast. Genes Dev. 24, 2705\u20132716 (2010).","journal-title":"Genes Dev."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncomms12308.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms12308","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms12308.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T05:38:53Z","timestamp":1672810733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncomms12308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,25]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,11,25]]}},"alternative-id":["BFncomms12308"],"URL":"https:\/\/doi.org\/10.1038\/ncomms12308","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,25]]},"assertion":[{"value":"4 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12308"}}